The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response

Cell Death Dis. 2016 Jul 21;7(7):e2299. doi: 10.1038/cddis.2016.211.

Authors

C Botta¹, G Misso², E C Martino³, L Pirtoli³, M G Cusi⁴, P Tassone¹, P Tagliaferri¹, M Caraglia², P Correale³

Affiliations

¹ Department of Clinical and Experimental Medicine, Magna Graecia University, Catanzaro, Italy.
² Department of Biochemistry, Biophysics and General Pathology, Second Naples University, Naples, Italy.
³ Department of Oncology, Siena, Italy.
⁴ Department of Medical Biotechnology University of Siena, Siena, Italy.

No abstract available

MeSH terms

Animals
Bevacizumab / therapeutic use
Humans
Immunomodulation
Inflammation / pathology*
Models, Biological
Neoplasms / blood supply*
Neoplasms / drug therapy
Neoplasms / immunology*
Neovascularization, Pathologic / drug therapy
Neovascularization, Pathologic / pathology*

Substances

Bevacizumab